[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-461967-105":59,"doc-detail-461967-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","association-between-mefox-and-prevalence-of-copd-evidence-from-nhanes-2011-2020","Association Between Mefox and Prevalence of COPD: Evidence from NHANES 2011-2020","","Objective: Investigate the relationship between Mefox levels and the prevalence of chronic obstructive pulmonary disease (COPD) using NHANES data from 2011–2020. Methods: Analysis included 9525 participants after excluding incomplete data. COPD was defined by self-reported diagnoses, while Mefox was quantified via HPLC-MS/MS. Logistic regression with demographic and clinical covariate adjustments assessed associations, and restricted cubic spline models examined dose-response patterns. Results: Weighted COPD prevalence was 4.0%; higher Mefox associated with increased COPD risk, with a nonlinear relationship and consistent subgroup findings. Conclusions: Elevated Mefox links to higher COPD risk, implicating folate metabolism disruption and inflammation; further studies are needed for therapeutic targeting.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/association-between-mefox-and-prevalence-of-copd-evidence-from-nhanes-2011-2020/461967/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/association-between-mefox-and-prevalence-of-copd-evidence-from-nhanes-2011-2020/461967.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the objective of this NHANES-based study?","Question",{"text":113,"@type":114},"To evaluate whether Mefox levels are associated with the prevalence of COPD using NHANES data collected between 2011 and 2020.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were COPD and Mefox measured in the study?",{"text":118,"@type":114},"COPD was defined using self-reported diagnoses, while Mefox levels were measured using HPLC-MS/MS techniques.",{"name":120,"@type":111,"acceptedAnswer":121},"What statistical approaches were used to assess the association?",{"text":122,"@type":114},"Logistic regression assessed associations with adjustments for demographic and clinical covariates, and restricted cubic spline regression explored the dose-response relationship and nonlinearity.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},461967,1790794875,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article  \nAssociation Between Mefox and Prevalence of COPD: Evidence from NHANES 2011–2020  \nLong Liang *,†, Ying Luo † and Yongchang Sun *  \nDepartment of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing 100191, China; [luoying@stu.pku.edu.cn](luoying@stu.pku.edu.cn)  \n* Correspondence: [2316394110@bjmu.edu.cn](2316394110@bjmu.edu.cn) (L.L.); [suny@bjmu.edu.cn](suny@bjmu.edu.cn) (Y.S.)  \n† These authors contributed equally to this work.  \nAbstract  \nObjective: This study aimed to investigate the relationship between Mefox (a pyrazino-striazine derivative of 4α-hydroxy-5-methyl-tetrahydrofolate and an oxidative stress marker derived from folate metabolism) levels and the prevalence of Chronic Obstructive Pulmonary Disease (COPD) using data from the National Health and Nutrition Examination Survey (NHANES) collected between 2011 and 2020 . Methods: The analysis included 9525 participants after excluding those with incomplete data. COPD was defined through self-reported diagnoses, while Mefox levels were measured using HPLC-MS/MS techniques. Logistic regression analyses were conducted to assess the association between Mefox and COPD prevalence, with adjustments for demographic and clinical covariates. Restricted cubic spline (RCS) regression models were employed to explore the dose–response relationship. Results: The weighted prevalence of COPD was found to be 4.0% . Higher Mefox levels were significantly associated with increased COPD risk (p = 0.00117, odds ratio [OR] 1.72, 95% confidence interval [CI] 1.24–2.39) . A nonlinear association was observed, with risk stability at lower Mefox levels, followed by a significant increase at higher levels. Subgroup analyses revealed consistent associations across demographics, with significant interactions noted in age > 70 years adults and individuals with BMI ≥ 25. Additionally, inflammatory markers showed significant correlations with Mefox levels. Conclusions: The findings highlight a significant association between elevated Mefox levels and increased COPD risk, suggesting that disruptions in folate metabolism and inflammation may play crucial roles in COPD pathogenesis. These results underscore the need for further research to explore potential therapeutic interventions targeting folate metabolism in COPD management.  \nAcademic Editors: Eleonore Fröhlich and Marco Dettori  \nReceived: 28 October 2025  \nRevised: 18 December 2025  \nAccepted: 19 December 2025  \nPublished: 23 December 2025  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nKeywords: COPD; Mefox; logistic regression model; RCS regression model; inflammatory  \n1. Introduction  \nChronic Obstructive Pulmonary Disease (COPD) is a leading cause of global morbidity and mortality, characterized by persistent respiratory symptoms and progressive, irreversible airflow limitation [1] . COPD places a substantial burden on healthcare systems [2], with primary risk factors including smoking, environmental pollutants, and occupational exposures. Despite these well-established contributors, emerging evidence suggests that oxidative stress [3,4] plays a crucial role in the development and progression of COPD. Oxidative stress occurs when there is an imbalance between the production of reactive  \noxygen species (ROS) and the body’s antioxidant defenses, leading to cellular damage, inflammation, and the gradual decline in lung function observed in COPD patients.  \nThe potential connection between folate metabolism [5] and COPD has gained increasing attention, as folate is essential for DNA synthesis, repair [6], and methylation [7] . Mefox (a pyrazino-s-triazine derivative of 4α-hydroxy-5-methyl-tetrahydrofolate) is an oxidation product of 5-methyl-tetrahydrofolate (5-mTHF), a critical form of folate. When oxidative stress occurs in the body, 5-mTHF ca","cbCaiendidKjUQ0I","https://ap.wps.com/l/cbCaiendidKjUQ0I","pdf",861802,"English","# Introduction\n# Materials and Methods\n## Study Population and Design","[{\"question\":\"What was the objective of this NHANES-based study?\",\"answer\":\"To evaluate whether Mefox levels are associated with the prevalence of COPD using NHANES data collected between 2011 and 2020.\"},{\"question\":\"How were COPD and Mefox measured in the study?\",\"answer\":\"COPD was defined using self-reported diagnoses, while Mefox levels were measured using HPLC-MS/MS techniques.\"},{\"question\":\"What statistical approaches were used to assess the association?\",\"answer\":\"Logistic regression assessed associations with adjustments for demographic and clinical covariates, and restricted cubic spline regression explored the dose-response relationship and nonlinearity.\"}]","Association Between Mefox and Prevalence of COPD: Evidence from NHANES 2011-2020 | PDF",1790762903,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/918454593951541810f04a13236893b6.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/3f8b40ffe4e98cb1fd528d70171da844.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/aa9d042d5f142a8c3eee512f56e73f4b.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/91ecd41e3cd5e1627f0eb148ecb7b53a.webp",980,1385]